Linden Thomas Advisory Services LLC Raises Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Linden Thomas Advisory Services LLC boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,699 shares of the company’s stock after purchasing an additional 96 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Neurocrine Biosciences were worth $842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of NBIX. Geneos Wealth Management Inc. raised its position in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. WPG Advisers LLC bought a new position in Neurocrine Biosciences in the first quarter valued at $32,000. Smallwood Wealth Investment Management LLC bought a new stake in Neurocrine Biosciences during the first quarter worth about $34,000. SVB Wealth LLC purchased a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $35,000. Finally, Golden State Wealth Management LLC increased its position in shares of Neurocrine Biosciences by 116.9% during the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock valued at $44,000 after purchasing an additional 214 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 0.2%

Shares of NBIX opened at $144.00 on Monday. The stock has a market capitalization of $14.28 billion, a P/E ratio of 42.60, a PEG ratio of 0.98 and a beta of 0.21. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $154.61. The firm has a fifty day simple moving average of $139.94 and a two-hundred day simple moving average of $128.02.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The company’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.63 earnings per share. Sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Royal Bank Of Canada upped their target price on Neurocrine Biosciences from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a report on Thursday, July 10th. They issued a “buy” rating and a $182.00 price objective for the company. Zacks Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Saturday. Finally, Citigroup began coverage on Neurocrine Biosciences in a research note on Tuesday, October 21st. They set a “buy” rating and a $175.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $164.32.

Insider Buying and Selling

In related news, Director Kevin Charles Gorman sold 106,322 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the transaction, the director owned 514,596 shares in the company, valued at $65,050,080.36. This represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.